StockDriftsStockDriftsTop 14 Johnson & Johnson Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PTGX | PROTAGONIST THERAPEUTICS INC | 37.59% | 2.45M | $300.2M | +0.00%(+0) | $31.30(+374.30%) | 2026-06-30 | |
| NBTX | NANOBIOTIX | 26.55% | 5.62M | $212.0M | +0.00%(+0) | $7.83(+401.89%) | 2026-06-30 | |
| MGTX | MEIRAGTX HLDGS PLC | 11.23% | 6.64M | $89.7M | +0.00%(+0) | $10.47(+22.69%) | 2026-06-30 | |
| RAPP | RAPPORT THERAPEUTICS INC | 9.31% | 1.78M | $74.4M | +0.00%(+0) | $23.26(+107.03%) | 2026-06-30 | |
| CTNM | CONTINEUM THERAPEUTICS INC | 4.06% | 1.98M | $32.4M | +0.00%(+0) | $17.61(-17.49%) | 2026-06-30 | |
| LEGN | LEGEND BIOTECH CORP | 2.95% | 814.6K | $23.5M | +0.00%(+0) | $45.81(-52.69%) | 2026-06-30 | |
| CVRX | CVRX INC | 2.59% | 4.02M | $20.7M | +0.00%(+0) | $22.65(-89.09%) | 2026-06-30 | |
| XNCR | XENCOR INC | 1.51% | 748.1K | $12.0M | +0.00%(+0) | $36.39(-40.62%) | 2026-06-30 | |
| FATE | FATE THERAPEUTICS INC | 1.14% | 3.38M | $9.1M | +0.00%(+0) | $73.03(-96.30%) | 2026-06-30 | |
| PRCT | PROCEPT BIOROBOTICS CORP | 1.01% | 357.9K | $8.1M | +0.00%(+0) | $38.15(-43.70%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (19 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | +26.84% | +104.06% | — | — | +15.58% |
| Top 20 Holdings Unweighted | +13.23% | +45.16% | — | — | -14.24% |
Johnson & Johnson reports $798.65M in US-listed equity holdings across 15 positions in its most recent 13F filing. Its largest disclosed positions are PTGX (37.6%), NBTX (26.6%) and MGTX (11.2%). The top 20 holdings account for 98.5% of reported assets. Its disclosed equity book has returned +104.06% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Sign up free to track Johnson & Johnson, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Johnson & Johnson’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 200406). View Johnson & Johnson’s 13F filings on SEC